The purpose of this study is to assess the safety and effect of TC-5214 as a single therapy in patients with major depressive disorder who exhibit inadequate response to antidepressants.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
145
Tablet, oral, twice daily for 8 weeks
Capsule, oral, once daily
Tablet, oral, twice daily for 8 weeks
Change in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score From Randomization to End of Treatment
A 10-item scale for the evaluation of depressive symptoms. Each Montgomery Asberg Depression Rating Scale (MADRS) item is rated on a 0 to 6 scale. The MADRS total score is calculated as the sum of the 10 individual item scores; the total score can range from 0 to 60. Higher MADRS scores indicate higher levels of depressive symptoms.
Time frame: Randomization (Week 8) to end of treatment (Week 16)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Research Site
Beverly Hills, California, United States
Research Site
Chino, California, United States
Research Site
Garden Grove, California, United States
Research Site
San Diego, California, United States
Research Site
Torrance, California, United States
Research Site
Bradenton, Florida, United States
Research Site
Coral Springs, Florida, United States
Research Site
Jacksonville, Florida, United States
Research Site
North Miami, Florida, United States
Research Site
St. Petersburg, Florida, United States
...and 53 more locations